Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Ruth M De Tute, BSc,MSc, Debbie Sherratt, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 802.

https://doi.org/10.1182/blood-2018-99-116426

Published: 2018

Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 306.

https://doi.org/10.1182/blood-2018-99-116624

Published: 2018

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD

Blood (2017) 130 (Supplement 1): 835.

https://doi.org/10.1182/blood.V130.Suppl_1.835.835

Published: 2017

Journal Articles

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Amy L Sherborne, PhD, Vallari Shah, MBBS, Sidra Ellis, Farzana Begum, Jack Kendall, David C Johnson, Roger G Owen, MD, Mark T Drayson, MD PhD, Louise Flanagan, Debbie Sherratt, Walter M Gregory, PhD, Graham Jackson, MDPhD, Guy Pratt, MD FRCP, FRCPath, Gordon Cook, MD PhD, Samantha Hinsley, Sarah Brown, Matthew W Jenner, Martin F Kaiser, MD

Blood (2017) 130 (Supplement 1): 1767.

https://doi.org/10.1182/blood.V130.Suppl_1.1767.1767

Published: 2017

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Kwee L Yong, MBChB, PhD, Sarah Brown, Samantha Hinsley, Louise Flanagan, Neil Rabin, MB,BS, PhD, Karthik Ramasamy, Jamie Cavenagh, Roger G Owen, Martin F Kaiser, MD, Eric Low, Catherine Williams

Blood (2015) 126 (23): 1840.

https://doi.org/10.1182/blood.V126.23.1840.1840

Published: 2015

Journal Articles

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

Annamaria Brioli, MD, Charlotte Pawlyn, MD, Walter Gregory, PhD, Samantha Hinsley, MSc, Samantha Marshall, Jindriska Lindsay, MD, Claire Chapman, MD, Gordon Cook, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Michele Cavo, MD, Graham H Jackson, MD, Nigel Russel, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 2074.

https://doi.org/10.1182/blood.V122.21.2074.2074

Published: 2013

Journal Articles

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

Charlotte Pawlyn, MD, Annamaria Brioli, MD, Walter Gregory, PhD, Samantha Hinsley, MSc, Jindriska Lindsay, MD, Gordon Cook, MD, PhD, Donald Milligan, MD, Claire Chapman, MD, Roger G Owen, MD, Mark T Drayson, MD PhD, Nigel Russell, MD, Graham H Jackson, MD, Faith E Davies, MD, Gareth J Morgan, MD PhD

Blood (2013) 122 (21): 540.

https://doi.org/10.1182/blood.V122.21.540.540

Published: 2013

NARROW

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

Email alerts

ASH Publications

American Society of Hematology

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Newly Diagnosed Multiple Myeloma (MM) Patients Treated With Lenalidomide Induction and Maintenance Show a Low Incidence Of Second Primary Malignancies (SPMs)

Lenalidomide Combined With Cyclophosphamide and Dexamethasone Is Effective and Well Tolerated Induction Treatment For Newly Diagnosed Myeloma Patients Of All Ages

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only